Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137075

Published: 2020

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Blood (2016) 128 (22): 1145.

https://doi.org/10.1182/blood.V128.22.1145.1145

Published: 2016

Journal Articles

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli, MD

Blood (2010) 116 (21): 5030.

https://doi.org/10.1182/blood.V116.21.5030.5030

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Simona Bassi, Simona Sammassimo, Federica Gigli, Giancarlo Pruneri, Paola Bertazzoni, Jessica Quarna, Emilia Cocorocchio, Daniele Laszlo, Mara Negri, Maria Lionetti, Anna Vanazzi, Alessandra Alietti, Alberto Agazzi, Angelo Gardellini, Giovanna Andreola, Lorenzo Preda, Rocco Pastano, Giovanni Martinelli, MD

Blood (2010) 116 (21): 3956.

https://doi.org/10.1182/blood.V116.21.3956.3956

Published: 2010

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Paola Bertazzoni, Cristina Rabascio, Liliana Calabrese, Federica Gigli, Simona Bassi, MD, Luca Nassi, Simona Sammassimo, Sara Steffanoni, Davide Radice, Angelica Calleri, Emilia Cocorocchio, Daniele Laszlo, Giovanni Martinelli

Blood (2008) 112 (11): 3171.

https://doi.org/10.1182/blood.V112.11.3171.3171

Published: 2008

Journal Articles

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Simona Bassi, MD, Federica Gigli, Cristina Rabascio, Simona Sammassimo, Patrizia Mancuso, Emilia Cocorocchio, Paola Bertazzoni, Daniele Laszlo, Giancarlo Pruneri, Liliana Calabrese, Maria Teresa Lionetti, Anna Vanazzi, MD, Alessandra Alietti, Luca Nassi, Alberto Agazzi, Rocco Pastano, Fedro Alessandro Peccatori, Giovanni Martinelli

Blood (2008) 112 (11): 5016.

https://doi.org/10.1182/blood.V112.11.5016.5016

Published: 2008

Journal Articles

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Federica Gigli, Luca Nassi, Mara Negri, Laura Travaini, Sara Steffanoni, Sarah Jane Liptrott, Patrizia Mancuso, Paola Bertazzoni, Simona Bassi, MD, Liliana Calabrese, Emilia Cocorocchio, Giovanni Martinelli

Blood (2008) 112 (11): 3607.

https://doi.org/10.1182/blood.V112.11.3607.3607

Published: 2008

Journal Articles

Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.

Simona Bassi, MD, Alessandra Alietti, MD, Chiara Corsini, DSc, Federica Gigli, MD, Paola Bertazzoni, MD, Cristina Rabascio, DSc, Patrizia Mancuso, DSc, Emilia Cocorocchio, MD, Daniele Laszlo, MD, Giancarlo Pruneri, MD, Lorenzo Preda, MD, Sarah J. Liptrott, BN, Rosaria Cascio, PH, Francesco Bertolini, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 5116.

https://doi.org/10.1182/blood.V110.11.5116.5116

Published: 2007

NARROW

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only